Immunocore Holdings IMCR
NASDAQ IMCR
$36.33 -1.24 (-3.30%)
As of: Sep 4, 2026 · 2:39 PM EDT

Immunocore Holdings (IMCR) Income towards Parent Company (2021 - 2026)

Immunocore Holdings (IMCR) posted Income towards Parent Company of $13.0 million for Q1 2026, up 143.15% sequentially from -$30.1 million in Q4 2025, and up 160.25% YoY from $5.0 million in Q1 2025.

Analysis

Immunocore Holdings (IMCR) Income towards Parent Company (2021 - 2026) Analysis & Trends

Immunocore Holdings has reported Income towards Parent Company for 6 years, with the latest figure at $13.0 million in Q1 2026.

  • Quarterly Income towards Parent Company rose 160.25% year-over-year to $13.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$27.6 million (down 27.23% YoY) and the FY2025 annual result came in at -$35.5 million, up 30.48% from the prior year.
  • Income towards Parent Company grew to $13.0 million in Q1 2026 per IMCR's latest filing, from -$30.1 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $13.0 million in Q1 2026 and troughed at -$30.1 million in Q4 2025.
  • A 5-year average of -$10.7 million and a median of -$14.6 million in 2023 frame the typical range for Income towards Parent Company.
  • The sharpest annual moves came in 2024 and 2025: Income towards Parent Company jumped 864.24% in 2024, then plunged 102.24% in 2025.
  • Over 5 years, Income towards Parent Company stood at -$29.9 million in 2022, then jumped by 33.95% to -$19.7 million in 2023, then fell by 20.48% to -$23.8 million in 2024, then retreated by 26.46% to -$30.1 million in 2025, then jumped by 143.15% to $13.0 million in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered $13.0 million, -$30.1 million, and -$196000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.74 Bn 130.89 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.52 Bn 77.52 Bn 3.93 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn
4 Moderna 58.04 Bn 52.91 Bn 52.00 Mn
5 Revolution Medicines 44.06 Bn 44.06 Bn -
6 BeOne Medicines 39.98 Bn 34.88 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.46 Bn 32.15 Bn 992.69 Mn
8 Royalty Pharma 28.41 Bn 27.57 Bn -
9 Insmed 27.44 Bn 26.28 Bn 358.27 Mn
10 Immunocore Holdings 1.85 Bn 971.91 Mn 114.84 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -814,000.00
Mar 31, 2026 12.97 Mn
Dec 31, 2025 -30.06 Mn
Sep 30, 2025 -196,000.00
Jun 30, 2025 -10.30 Mn
Mar 31, 2025 4.98 Mn
Dec 31, 2024 -23.77 Mn
Sep 30, 2024 8.74 Mn
Jun 30, 2024 -11.63 Mn
Mar 31, 2024 -24.48 Mn
Dec 31, 2023 -19.73 Mn
Sep 30, 2023 906,000.00
Jun 30, 2023 -17.62 Mn
Mar 31, 2023 -19.46 Mn
Dec 31, 2022 -29.56 Mn
Sep 30, 2022 7.34 Mn
Jun 30, 2022 -19.69 Mn
Dec 31, 2021 -53.10 Mn
Sep 30, 2021 -41.54 Mn